PRODUCT INFORMATION



6(S)-Lipoxin A₄

CAS Registry No.: Formal Name:	94292-80-5 5S,6S,15S-trihydroxy-7E,9E,11Z,13E-				
	eicosatetraenoic acid				
Synonyms:	5(S),6(S)-Lipoxin A ₄ , 6- <i>epi</i> -Lipoxin A ₄ , 6(S)-LXA ₄ , 5(S),6(S),15(S)-TriHETE				
MF:	$C_{20}H_{32}O_5$				
FW:	352.5				
Purity:	≥95%				
Supplied as:	A solution in ethanol	ОН			
UV/Vis.:	λ _{max} : 302 nm ε: 50,000	OH			
Storage:	-80°C				
Stability:	≥1 year				
Miscellaneous:	Light Sensitive				
Information memory to the man dust and if a time. Betch and if any hold in a man ideal and and any sector of an abusia					

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

6(S)-Lipoxin A₄ (6(S)-LXA₄) is supplied as a solution in ethanol. To change the solvent, simply evaporate the 6(S)-LXA₄ under a gentle stream of nitrogen and immediately add the solvent of choice. Solvents such as dimethyl formamide purged with an inert gas can be used. The solubility of 6(S)-LXA₄ in this solvent is approximately 50 mg/ml.

6(S)-LXA₄ is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, the 6(S)-LXA₄ solution of ethanol should be diluted with the aqueous buffer of choice. The solubility of 6(S)-LXA₄ in PBS (pH 7.2) is approximately 1 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

6(S)-LXA₄ is an isomer of the trihydroxy fatty acid LXA₄ (Item No. 90410). It is formed from arachidonic acid (Item Nos. 90010 | 90010.1 | 10006607) through double lipoxygenase-catalyzed reactions initiated by either 5-lipoxygenase (5-LO) followed by 12- or 15-LO, with a leukotriene A_{4} (LTA₄) intermediate, or by 15-LO followed by 5-LO, with 15(S)-HETE (Item No. 34720) and 5(S)-Hp-15(S)-HETE intermediates.¹ The generation of 6(S)-LXA₄ and LXA₄ typically requires transcellular metabolism of arachidonic acid.^{1,2} For example, LTA₄ synthesized in neutrophils by 5-LO is metabolized to LXA₄ in platelets by 12-LO.¹ 6(S)-LXA4 has been detected in co-incubations of human polymorphonuclear leukocytes (PMNs) and platelets.³

References

- 1. Serhan, C.N. and Sheppard, K.-A. Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro. J. Clin. Invest. 85(3), 772-780 (1990).
- 2. Serhan, C.N., Chiang, N., and Van Dyke, T.E. Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8(5), 349-361 (2008).
- 3. Homann, J., Lehmann, C., Kahnt, A.S., et al. Chiral chromatography-tandem mass spectrometry applied to the determination of pro-resolving lipid mediators. J. Chromatogr. A 1360, 150-163 (2014).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 09/07/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM